Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen raised its price target for Incyte to $128 from $101 with a Buy rating on the shares. The firm’s optimism follows Incyte’s presentation of a strategic roadmap aimed at potentially tripling its revenue, excluding Jakafi, by 2029. With several Phase 3 trial readouts and initiations scheduled, the firm views 2026 as a pivotal year for both execution and delivery for the company. Furthermo ...

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings action stands in contrast to Wells Fargo’s downgrade of Incyte Corp (NASDAQ:INCY) to Equal Weight from Overweight on January 20. According to Wells Fargo, which also lowered the stock’s price target to $107 from $116, the downgrade reflects the company’s current valuation a ...

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC). ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks receive an alphabetic rating from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank and Style Scores - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [9] Stock Selection Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to maximize upside potential [10] Company Spotlight: Incyte Corporation - Incyte Corporation, based in Wilmington, DE, is a biopharmaceutical company engaged in developing proprietary therapeutics [12] - Currently rated 3 (Hold) with a VGM Score of A, Incyte has a Momentum Style Score of A and has seen a 1.9% increase in shares over the past four weeks [12][13] - The earnings estimate for fiscal 2025 has been revised upwards, with the Zacks Consensus Estimate now at $6.88 per share, reflecting an average earnings surprise of +14.4% [13]

Core Viewpoint - The article reflects a personal journey of an individual with a background in engineering who has developed a strong interest in investing, particularly in technology stocks, over the past 15 years [1]. Group 1 - The individual has over 30 years of experience as a Merchant Seaman, which has contributed to a global perspective [1]. - The interest in investing was significantly influenced by resources from The Motley Fool [1]. - The individual currently holds no stock, options, or similar derivative positions in any mentioned companies and has no plans to initiate any such positions in the near future [1].

Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Core Insights - The article highlights the professional background of Brendan, who has extensive experience in the pharmaceutical and biotechnology sectors, including a Ph.D. in organic synthesis from Stanford University and significant roles at major companies like Merck and 1200 Pharma [1] Group 1: Professional Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013, gaining experience in a major pharmaceutical company [1] - Brendan has been involved in biotech startups, including Theravance and Aspira, before joining Caltech [1] Group 2: Entrepreneurial Ventures - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the eight-figure range [1] - Brendan remains an avid investor, focusing on market trends, particularly in biotechnology stocks [1]

Group 1 - Brendan, a Pennsylvanian, completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira before joining Caltech [1] - Brendan is the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the 8 figures [1] - He remains an avid investor focused on market trends, particularly in biotechnology stocks [1]

Group 1 - The article promotes a subscription service called Beyond the Wall Investing, which provides high-quality analysis of Wall Street buying and selling ideas [1] - Daniel Sereda is highlighted as the chief investment analyst at a family office, emphasizing his expertise in navigating vast amounts of information to extract critical investment ideas [1] - The investing group offers access to information prioritized by institutional market participants, indicating a focus on professional-grade analysis [1]

Core Insights - The presentation outlines the top 10 stock picks for 2026, emphasizing strong performance in previous years and the potential for continued growth in the current market environment [10][99]. Market Overview - The financial markets experienced significant volatility in 2025, with technology stocks rising by 25% and communication services by 22%, while consumer staples finished in the red [13][12]. - The S&P 500 saw a decline of nearly 20% at one point, with the top stocks for 2025 down more than 20% before rebounding to finish up close to 45% [14][23]. - Gold reached historic highs during this period, driven by global economic uncertainties and increased central bank purchases [15]. AI and Technology Sector - The AI sector played a crucial role in market dynamics, with the "Mag 7" stocks trading at a forward P/E of 31x compared to the S&P 493 at 22x, indicating a significant premium for AI-driven companies [16][17]. - Hyperscalers like Amazon, Google, and Microsoft have increased their capital expenditures on AI infrastructure, raising concerns about the return on investment for these projects [18]. Stock Performance and Recommendations - Micron Technology (MU) is highlighted as a top pick with a market cap of $355 billion, showing a 254% increase over the past year and strong growth metrics [40][41]. - Advanced Micro Devices (AMD) has a market cap of $363 billion and a one-year return of 70%, with improved valuation metrics [52][53]. - Ciena Corporation (CIEN) has a market cap of $34 billion and a one-year return of 166%, with strong analyst revisions indicating positive sentiment [58][59]. - Celestica (CLS) and Coherent (COHR) are also noted for their strong growth and profitability metrics, with significant year-over-year returns [65][69]. Financial Sector Insights - Allstate Corporation (ALL) has a market cap of $53 billion and is focusing on AI underwriting, showing strong EPS growth of 99% year-over-year compared to the financial sector's 14% [72][76]. - Incyte Corporation (INCY) is recognized for its positive earnings and diverse pipeline in biotechnology, with a market cap of $19 billion [81][84]. Mining and Industrial Sector - Barrick Mining Corporation (B) has a market cap of $16 billion and is diversifying into copper, with a forward EPS growth rate of 46% [86][90]. - Willdan Group (WLDN) has a market cap of $1.57 billion and shows strong growth metrics, with a 61% EPS diluted growth rate [91][94]. - ATI has a market cap of $16 billion and is noted for its profitability improvements and strong analyst revisions [95][98].